Haifa-based MeMed, a developer of devices to monitor the body’s immune state, announced on 19 April it has received a $9.2 million contract from the US Defense Threat Reduction Agency (DTRA) to complete development of a bedside device that will help distinguish between viral and bacterial infections.

Established in 1998 to integrate DoD activities addressing the threat of weapons of mass destruction, DTRA supports R&D activities that offer solutions to the often intractable problems presented by the covert use of such weapons against civilian or societal targets. It support of MeMed research aims to accelerate development of a next generation test and monitoring solution that exploits work the company has conducted over the last eight years.
“This joint effort, and our growing collaboration with other international stakeholders from industry and government, will facilitate the global availability of our tests aimed at combating antimicrobial resistance,” MeMed CEO, Eran Eden, stated.


MeMed’s diagnostic tools could save valuable time in medical disasters or serious security incidents. (Photo: MeMed)

- Mönch Publications - Latest Issues -

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.

I agreeMore Information